Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Kim, Dong Wook [VerfasserIn]  |
|---|
| | Saußele, Susanne [VerfasserIn] |
|---|
| Titel: | Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase |
|---|
| Titelzusatz: | the DASPERSE study |
|---|
| Verf.angabe: | Dong-Wook Kim, Susanne Saussele, Loretta A. Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese |
|---|
| E-Jahr: | 2018 |
|---|
| Jahr: | 20 March 2018 |
|---|
| Umfang: | 11 S. |
|---|
| Fussnoten: | Gesehen am 18.10.2019 |
|---|
| Titel Quelle: | Enthalten in: Annals of hematology |
|---|
| Ort Quelle: | Berlin : Springer, 1991 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 97(2018), 8, Seite 1357-1367 |
|---|
| ISSN Quelle: | 1432-0584 |
|---|
| Abstract: | Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, such as dasatinib, are available with the potential to reduce adverse events, improve tolerability, and support long-term treatment goals. We present the final, primary analysis of DASPERSE/CA180-400 (NCT01660906), an open-label, multicenter, phase IV study designed to determine whether chronic, low-grade nonhematologic adverse events in imatinib-treated patients improve after switching to dasatinib, without affecting efficacy. |
|---|
| DOI: | doi:10.1007/s00277-018-3295-8 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1007/s00277-018-3295-8 |
|---|
| | Verlag: https://link.springer.com/article/10.1007%2Fs00277-018-3295-8 |
|---|
| | DOI: https://doi.org/10.1007/s00277-018-3295-8 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | Adverse effects |
|---|
| | Chronic myeloid leukemia |
|---|
| | Quality of life |
|---|
| | Tyrosine kinase |
|---|
| K10plus-PPN: | 1679109596 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase / Kim, Dong Wook [VerfasserIn]; 20 March 2018 (Online-Ressource)
68441979
